Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Janssen,Ibrutinib,"Chronic lymphocytic leukaemia (CLL),  previously untreated patients (17p deletion) and relapsed/refractory patients for whom ibrutinib is a more appropriate option (alternate)",Ibrutinib (Imbruvica),,Community,Oncology Agents and Immunosuppressants
